|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 2.65 Billion
|
|
Market Size (2030)
|
USD 3.98 Billion
|
|
CAGR (2025-2030)
|
7.08%
|
|
Fastest Growing Segment
|
Monoclonal Antibodies (mAb)
|
|
Largest Market
|
North India
|
Market Overview
India Immunology Drugs Market was valued at USD 2.65 Billion in 2024 and is expected to reach USD 3.98 Billion by 2030 with a CAGR of 7.08% during the forecast period. The Immunology Drugs Market refers to the global industry for
medicinal products designed to treat, prevent, or mitigate diseases related to
the immune system. This market includes drugs for a wide array of conditions
such as rheumatoid arthritis, psoriasis, Crohn's disease, and various forms of
immunodeficiencies. The sector has witnessed significant growth due to factors
such as increasing prevalence of immunological disorders, advancements in
biologic therapies, and the advent of biosimilars. It encompasses a broad
spectrum of therapeutics, including monoclonal antibodies, vaccines, and
immunosuppressive drugs.
In
recent years, there has been a remarkable surge in research and development
efforts to address the complex mechanisms underlying immune-related diseases.
This has led to the discovery of novel targets and the development of
innovative immunotherapies that show promising outcomes in clinical trials. The growing understanding of the immune system's intricate
workings has paved the way for personalized medicine approaches, allowing for
tailored treatments based on an individual's immune profile. The
Immunology Drugs Market has witnessed collaborations between pharmaceutical
companies, academic institutions, and research organizations to foster
innovation and accelerate the development of breakthrough therapies. This
collaborative ecosystem has fueled the introduction of next-generation
immunomodulatory drugs, aiming to provide safer and more effective treatment
options for patients.
As
the global population continues to face the burden of immune-related disorders,
the Immunology Drugs Market is projected to experience sustained growth in the
coming years. The demand for immunotherapies is anticipated to rise as
healthcare systems focus on improving patient outcomes and quality of life.
With ongoing advancements in technology and a deeper understanding of
immunology, the future of this market holds great potential for transformative
treatments that can revolutionize the way we combat immune-related diseases.
Key Market Drivers
Rising
Burden of Chronic Diseases
India
is currently experiencing a significant and alarming increase in the burden of
chronic diseases, particularly autoimmune disorders and cancers. According
to the International Agency for Research on Cancer (IARC), in 2022, India
reported 1,413,316 new cancer cases and 916,827 cancer-related deaths.
This rise has
led to an unprecedented demand for immunology drugs that can effectively combat
these conditions. Recent research has shown that lifestyle-related diseases and
an aging population are major contributors to this surge. Infections
and environmental triggers have further exacerbated the situation, resulting in
a higher prevalence of chronic inflammatory diseases. According to National Library of Medicine, About 21% of the elderly in India reportedly have at least one chronic disease. Seventeen percent elderly in rural areas and 29% in urban areas suffer from a chronic disease. Hypertension and diabetes account for about 68% of all chronic diseases.
In
response to this challenging scenario, there is a growing need for innovative
and efficient treatments, further driving the demand for immunology drugs.
These drugs play a crucial role in managing chronic conditions by reducing
inflammation and modulating the immune response. As a result, pharmaceutical
companies are now placing a higher priority on the development and distribution
of these drugs within India. However, it is important to address several
significant challenges to ensure that these life-saving drugs are accessible
and affordable for those in need. The affordability and accessibility of
immunology drugs must be tackled to ensure that they reach all segments of
society. Despite these challenges, the increasing demand for immunology drugs
is a clear indication of a proactive response to the escalating burden of
chronic diseases in India.
Increasing
Research in the Area of Next Generation Drugs
The
field of immunology drugs in India is experiencing remarkable growth, driven by
extensive research in the domain of next-generation drugs. Pioneering
advancements in biomedical science are leading to the development of innovative
therapeutics that specifically target immune-mediated diseases. With its robust
pharmaceutical industry, India is at the forefront of this revolutionary
progress. The surge in demand for immunology drugs is fueled by two key
factors. The emergence of novel drug mechanisms that precisely target
specific components of the immune system, offering enhanced efficacy and fewer
side effects. The increasing prevalence of immune-related diseases in
India, including rheumatoid arthritis and multiple sclerosis, necessitates the
urgent need for advanced therapeutics.
In
response to this demand, Indian pharmaceutical companies are heavily investing
in research and development activities focused on next-generation immunology
drugs. The government's support, through favorable policies and
funding, has further catalyzed this growth. As a result, not only is the demand
for immunology drugs rising, but India is also positioning itself as a global
hub for immunology drug research and manufacturing. This remarkable progress in
the field of immunology drugs in India signifies the country's commitment to
advancing healthcare and addressing the growing medical needs of its
population. With continued research and development, India is poised to make
significant contributions to the field of immunology and improve the lives of
countless individuals worldwide.
Increasing
Focus on Targeted Therapies
The
increasing focus on targeted therapies is significantly escalating the demand
for immunology drugs in India. These therapies, meticulously designed to act
specifically on immune responses associated with various diseases, have
revolutionized the treatment landscape. They have shown remarkable efficacy in
managing several conditions, particularly autoimmune and inflammatory diseases,
which have been a growing burden in India. As the prevalence of these diseases
continues to rise, there is a heightened need for effective and targeted
treatment strategies.
Immunology
drugs, with their precise action on immune pathways, present a promising
solution in addressing these healthcare challenges. The advent of personalized
medicine, coupled with the government's push for better healthcare
infrastructure and enhanced accessibility, further fuels the demand for these
drugs. Awareness programs conducted by pharmaceutical companies and
healthcare organizations have played a pivotal role in enlightening both
healthcare providers and patients about the benefits of these therapies,
reinforcing their adoption. Therefore, the focus on targeted therapies not only
meets the evolving healthcare needs but also propels the growth of the
immunology drugs market in India. This surge in demand marks the beginning of a
new era in disease management and patient care, where personalized and targeted
treatments take center stage.
Increased
Focus on R&D
The
burgeoning focus on research and development (R&D) in India has led to a
significant uptick in the demand for immunology drugs in the country. With its
globally recognized pharmaceutical sector known for generic drugs production,
India is now making a transition towards the development of novel drugs,
particularly in the immunology segment. This shift has been fueled by expanding
healthcare infrastructure, increased government funding for R&D, and a
growing talent pool of researchers specializing in immunology.
In October 2022, Roche inaugurated the company's second state-of-the-art Global Analytics and Technology Center of Excellence (GATE) in Hyderabad, in south India. The Swiss drug maker is developing data science and advanced analytics-related capabilities at GATE Center in Hyderabad and plans to expand its offerings to include forecasting, data management, DevOps etc., in the future, according to V Simpson Emmanuel, managing director and CEO of Roche Pharma India.
The rising prevalence of autoimmune and inflammatory diseases in the Indian
population has intensified the need for effective immunology drugs. The
increased investment in R&D has thus not only enhanced India's capacity to
meet domestic demand but has also positioned it as a key player in the
international immunology market. This growing focus on R&D is creating a
fertile environment for the advancement of immunology and its applications in
the Indian pharmaceutical industry. As India continues to prioritize R&D in
the healthcare sector, it is paving the way for innovative breakthroughs in
immunology. The collaboration between academia, industry, and research institutions
is fostering a conducive ecosystem for the discovery and development of
cutting-edge immunology drugs. This, in turn, showcases India's commitment to
addressing the evolving healthcare needs of its population and contributing to
the global advancements in the field of immunology.
Download Free Sample Report
Key Market
Challenges
Stringent
Regulatory Policies
Immunology
drugs in India are facing a significant downturn in demand, primarily due to
the stringent regulatory policies implemented by the government. These
regulations, which are designed to ensure the safety, efficacy, and quality of
these drugs, have become a major challenge for pharmaceutical companies
operating in the country. The rigorous nature of these regulations imposes
substantial costs of compliance, resulting in an inevitable increase in the
overall price of immunology drugs. The time-consuming approval
process further exacerbates the situation by causing delays in the launch of
new drugs, leading to a decrease in their availability and subsequently, the
demand.
The strict post-marketing surveillance requirements add to the burden faced by
pharmaceutical companies as they have to allocate additional resources and
incur additional costs to comply with these regulations. While it is undeniable
that these regulations are crucial for safeguarding patient safety, their
strictness, combined with the increased costs they entail, have started
discouraging patients and healthcare providers, further contributing to the
decline in the demand for immunology drugs in India. In order to address this
issue, it is imperative for the government to strike a balance between ensuring
patient safety and creating an environment that encourages innovation and growth
in the pharmaceutical industry. This could involve streamlining the approval
process, providing incentives for research and development, and exploring ways
to reduce the compliance costs for pharmaceutical companies. By doing so, it
will not only help revive the demand for immunology drugs but also foster the
development of new and more effective treatments for patients in need.
Expensive
Treatment Cost
In
India, the high cost of immunology drugs is becoming a significant deterrent
for many patients seeking treatment, leading to a decrease in demand. These
drugs, which are essential in managing and treating autoimmune disorders, are
often priced beyond the average individual's financial capacity, making them
inaccessible to a large portion of the population, especially those in lower
economic brackets. The prohibitive cost is primarily due to the intricate
process of developing these highly specialized medicines, involving complex
biotechnology and rigorous clinical trials. The expenses incurred in research
and development, manufacturing, and distribution are then passed on to the end
consumers, further exacerbating the issue.
The lack of comprehensive health insurance coverage adds to the challenges
faced by patients. Without adequate coverage, individuals are left to bear the
burden of the high treatment costs, making it even more difficult for them to
access these life-saving drugs. The high treatment cost has led to a
significant drop in demand for immunology drugs, highlighting a pressing need
for policy changes, price regulation, and increased healthcare funding. These
measures are necessary to make such treatments accessible and affordable for
all individuals who are in need, ensuring that no one is denied proper medical
care due to financial constraints.
Key Market Trends
Increasing
Prevalence of Immunological Disorders
India
is witnessing a remarkable surge in the demand for immunology drugs, primarily
attributed to the escalating prevalence of immunological disorders. Diseases
like rheumatoid arthritis, psoriasis, and Crohn's disease, which are triggered
by the immune system's abnormal response, are increasingly being reported
across the country. This exponential increase in the incidence of such
disorders has created an urgent need for effective treatment strategies,
thereby driving the demand for immunology drugs.
This
surge in demand is also correlated with the heightened awareness and improved
diagnosis of these disorders within the Indian population. With better access
to healthcare facilities and advancements in medical technology, there has been
a significant improvement in the early detection and treatment of immunological
disorders. This, in turn, has further propelled the market for immunology drugs
in the country. The introduction of biosimilars, which are
affordable alternatives to costly biologic drugs, has played a pivotal role in
making immunology drugs more accessible and affordable to a larger section of
the population. This affordability factor has significantly contributed to
fueling the demand for immunology drugs in India. The increasing prevalence of
immunological disorders in India, coupled with improved awareness, accurate
diagnosis, and the availability of affordable drugs, is driving the growing
demand for immunology drugs in the country. These factors collectively paint a
picture of an evolving healthcare landscape in India, where the need for
effective immunology drugs continues to grow.
Innovation
and New Product Launches
Innovation
and new product launches in India's pharmaceutical sector are playing a
significant and transformative role in increasing the demand for immunology
drugs. This trend is driven by a combination of factors, including the
country's growing burden of autoimmune and inflammatory diseases, the rise of
cutting-edge research and development initiatives, and the increasing need for
advanced drugs with improved efficacy and fewer side effects.
The
entry of novel drugs into the market is particularly noteworthy, as they target
previously unaddressed conditions or offer better management of existing
diseases. This has led to a surge in demand for these drugs, as patients and
healthcare providers seek more effective treatment options. Increased
awareness and accessibility, supported by governmental health schemes and
growing private investment, have further fueled the demand for immunology drugs
in India. As a result, the landscape of immunology drugs in India is undergoing
a significant transformation, driven by innovation and the introduction of new
products. This transformation is not only benefiting patients by providing them
with better treatment options, but it is also opening up new opportunities for
pharmaceutical companies to expand their portfolios and contribute to the
overall growth of the sector.
Segmental Insights
Drug Class Insights
Based on the drug
class, monoclonal antibodies (mAb) currently hold a dominant position due to
its versatile role in managing a wide range of immunological diseases. With its
targeted approach and continuous efforts in research and development, the
application scope of mAb is constantly expanding. This is driven by the need to
address the evolving healthcare landscape and the increasing demand for
personalized treatment options. It is
worth noting that the market share of other drug classes, such as Antibody Drug
Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication,
among others, is also on the rise. These advancements can be attributed to the
progress in medical technology and the growing awareness of the importance of
maintaining good health. As the healthcare industry continues to evolve, it is
crucial to stay abreast of the latest developments in immunology drugs. The
market is witnessing significant growth and offers promising opportunities for
both pharmaceutical companies and healthcare professionals to contribute to the
well-being of patients and society as a whole.
Indication Insights
Based on indication,
the Arthritis segment is currently dominating the India Immunology Drugs
Market. This can be attributed to the high prevalence of arthritis, including
rheumatoid and osteoarthritis, among the population. The rising awareness about
the importance of early diagnosis and treatment has further fueled the growth
of this segment in the market. Advancements in medical research and
technology have led to the development of innovative immunology drugs
specifically tailored to target arthritis-related inflammation and provide
effective symptom relief. These drugs not only help manage pain and improve
mobility but also slow down disease progression, enhancing the quality of life
for arthritis patients. With an increasing number of individuals seeking these advanced
solutions for managing arthritis, the demand for immunology drugs in India is
expected to continue its upward trajectory.
The
India Immunology Drugs Market is also benefitting from strategic partnerships
and collaborations between pharmaceutical companies and research institutions.
This collaboration has facilitated the exchange of knowledge and resources,
leading to the development of more targeted and efficient immunology drugs. Government initiatives and healthcare policies focused on improving access to
healthcare services and raising awareness about arthritis and its treatment
options have played a significant role in driving the growth of the immunology
drugs market in India. These initiatives aim to reduce the burden of arthritis
on individuals and society as a whole, emphasizing the importance of early
intervention and comprehensive care. The India Immunology Drugs Market is
witnessing significant growth in the Arthritis segment, driven by factors such
as high prevalence, increased awareness, advancements in medical research, and
supportive government initiatives. The development of innovative immunology
drugs tailored to address arthritis-related inflammation has improved the
quality of life for arthritis patients and is expected to continue meeting the
growing demand for effective treatment options in the future.
Download Free Sample Report
Regional Insights
Based on the region, North India is anticipated to hold a
dominant position. This region boasts a robust healthcare infrastructure,
equipped with state-of-the-art medical facilities and a skilled workforce,
which enables efficient delivery of healthcare services to a large population. North India's geographical location and well-connected transportation
network facilitate the smooth distribution of immunology drugs across the
region. The high prevalence of autoimmune diseases in North India,
including rheumatoid arthritis, lupus, and psoriasis, further contributes to
its prominence in the market. The region's healthcare institutions are at the
forefront of research and treatment for these conditions, attracting patients
from across the country. The availability of specialized immunology drugs and a
strong network of healthcare facilities, including hospitals, clinics, and
diagnostic centers, ensures that patients in North India have access to the
latest treatments and comprehensive care. Considering
these factors, North India is expected to maintain its leading position in the
India Immunology Drugs Market for the foreseeable future. The region's
continuous efforts in healthcare advancement and its commitment to improving
patient outcomes make it a key player in driving the growth and development of
the immunology drugs market in India.
Recent Developments
- In May 2023, Sun Pharmaceutical Industries Ltd.
announced that the Chinese health authority has granted approval for its new
drug application (NDA) of tildrakizumab injection, intended for treating adults
suffering with moderate-to-severe plaque psoriasis. Marketed as Ilumetri, the
medication is specifically designated for adults diagnosed with
moderate-to-severe plaque psoriasis who are deemed suitable candidates for
systemic therapy or phototherapy.
- In
October 2023, India’s Central Drugs Standard Control Organization (CDSCO),
which serves as the counterpart to the US Food and Drug Administration,
approved NexCAR19 as the country's first CAR-T cell therapy. This approval was
based on the outcomes of two small clinical trials conducted in India,
involving 64 patients with advanced lymphoma or leukemia. The trial results,
presented at the American Society of Hematology meeting in December 2023,
showed that 67% of patients (36 out of 53) experienced a significant reduction
in cancer severity (objective response), with nearly half achieving complete
remission (complete response). ImmunoACT, a spin-off from IIT Bombay, funded
the trials and will be responsible for manufacturing actalycabtagene autoleucel
and commercializing it.
Key Market Players
- Panacea Biotec Ltd.
- Bristol-Myers Squibb India Pvt Ltd.
- Wockhardt Ltd.
- Pfizer Ltd.
- Sanofi India Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- Abbott India Ltd.
- Genetech Pvt Ltd.
- Novartis India Ltd.
- Allergan India Pvt Ltd.
|
By Drug Class
|
By Indication
|
By End User
|
By Region
|
- Monoclonal Antibodies (mAb)
- Antibody Drug Conjugates
- Interferon and Cytokine therapies
- Immunosuppressive medication
- Others
|
- Arthritis
- Plaque Psoriasis
- Spondylitis
- Inflammatory Bowel Disease
- Transplant Rejection
- Others
|
- Hospitals & Clinics
- Cancer Research Institute
- Others
|
|
Report
Scope:
In
this report, the India Immunology Drugs Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- India Immunology Drugs Market, By Drug Class:
o
Monoclonal Antibodies (mAb)
o
Antibody Drug Conjugates
o
Interferon and Cytokine therapies
o
Immunosuppressive medication
o
Others
- India Immunology Drugs Market, By Indication:
o
Arthritis
o
Plaque Psoriasis
o
Spondylitis
o
Inflammatory Bowel Disease
o
Transplant Rejection
o
Others
- India Immunology Drugs Market, By End User:
o
Hospitals
o
Clinics
o
Cancer Research Institute
o
Others
- India Immunology Drugs Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Immunology Drugs Market.
Available
Customizations:
India
Immunology Drugs Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of additional
market players (up to five).
India
Immunology Drugs Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]